Solriamfetol

Solriamfetol emerged from the JZP-110 program (originally ADX-N05 / YKP10A) and was approved by the FDA in 2019 and the EMA in 2020 for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. Mechanistically it is a dual dopamine and norepinephrine reuptake inhibitor with in vitro potency in the low micromolar range and negligible activity at the serotonin transporter; it lacks the amphetamine-type monoamine-releasing action, and preclinical work links its wake promotion specifically to dopamine and norepinephrine transporter blockade rather than to histamine or orexin systems.

In the pivotal TONES phase III narcolepsy trial the 150 mg and 300 mg doses produced significant, sustained gains on the Maintenance of Wakefulness Test and reductions on the Epworth Sleepiness Scale versus placebo, and the TONES 3 trial showed the same wake-promoting benefit across 37.5 to 300 mg in residual sleepiness of treated obstructive sleep apnea.

A prespecified subgroup analysis confirmed efficacy in narcolepsy with and without cataplexy, though solriamfetol did not itself reduce cataplexy attack frequency. Reviews position it as a first-line or replacement option when modafinil, armodafinil, pitolisant, or stimulants are inadequate or poorly tolerated. Comparative preclinical work groups its neurochemical and locomotor profile with modafinil and amphetamine rather than with the non-stimulant pitolisant, underlining a residual, if modest, psychostimulant character. The approved narcolepsy range is 75 to 150 mg once daily; 300 mg confers little added benefit with more adverse effects and is above the labelled maximum.

Common adverse reactions are headache, nausea, decreased appetite, insomnia, dry mouth, and anxiety, most appearing within the first two weeks and often resolving. Solriamfetol produces dose-related increases in blood pressure and heart rate, so blood pressure should be assessed and controlled before and during treatment and caution is warranted in cardiovascular disease. Late-day dosing can cause insomnia. It is renally eliminated, so dose reduction is required in moderate to severe renal impairment and it is not recommended in end-stage renal disease. Concurrent use with monoamine oxidase inhibitors is contraindicated. As a Schedule IV agent it carries a defined, though comparatively low, abuse potential.

Solriamfetol is subject to both pharmacokinetic and pharmacodynamic drug interactions. As a monoamine transporter inhibitor (dopamine and norepinephrine uptake inhibitor), it carries clinically significant interaction risk when combined with other sympathomimetics, serotonergic agents, or inhibitors of monoamine oxidase; concurrent use can precipitate hypertension, tachycardia, or a serotonin syndrome-like state ^[8]. Pharmacokinetically, solriamfetol interacts with drugs affecting its absorption and metabolism, though specific CYP enzyme data are limited in the primary literature.

Package labeling indicates caution with cardiovascular agents and psychiatric medications, particularly those affecting monoamine neurotransmission. Clinicians should review concomitant medications carefully, particularly stimulants, antidepressants with monoamine effects, and sympathomimetic decongestants, and should counsel patients to avoid over-the-counter cold remedies containing pseudoephedrine or similar agents ^[8].

Checking a whole stack? Run it through interactions + stacks.

The molecule was developed as ADX-N05 by Aerial BioPharma, advanced as JZP-110 after acquisition by Jazz Pharmaceuticals, approved by the FDA in March 2019 and the EMA in 2020, and later divested to Axsome Therapeutics. It is one of the first genuinely new wake-promoting mechanisms brought to market for excessive daytime sleepiness since modafinil.

Solriamfetol is regarded as an effective, generally well tolerated wakefulness agent that is distinguished from amphetamines by a lower abuse liability and from modafinil by a distinct dual dopamine and norepinephrine mechanism. It is valued as a switch or add-on option in patients incompletely controlled by, or intolerant of, older agents.